David Gailani
Last active: 1/20/2015


A dynamic balance exists between the processes that form a blood clot at the site of blood vessel injury (coagulation) and the processes responsible for removing the clot once healing has occurred (fibrinolysis). This equilibrium, referred to as hemostasis, is required to prevent excessive blood loss from a wound (bleeding) while avoiding occlusion of normal blood vessels (thrombosis). My laboratory is involved in studying the contribution of certain plasma clotting factors to the formation of fibrin clots in normal and pathologic conditions. We are particularly interested in the plasma serine proteases factors IX and XI. These enzymes appear to be required for consolidating the hemostatic process after initial clot formation. Excessive activity of either protein has been linked to formation of pathologic blood vessel thrombosis. Utilizing a combination of site-directed mutagenesis, production of recombinant proteins in mammalian tissue culture, enzymology and classic coagulation assays we are investigation structure/function relationships as they relate to the activation, the activity, and binding interactions involving factors IX and XI. We are applying similar approaches to investigations of the proteases responsible for converting inactive factor XI to the active form factor XIa. More recently, we have been investigating the contributions of factors IX and XI to hemostasis and thrombosis in vivo, using factor IX and factor XI deficient mice. These proteins appear to play important roles in the formation of abnormal occlusive thrombi in mouse models, and may be attractive targets for drugs to prevent or treat blood vessel thrombosis in human patients.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Excess of heme induces tissue factor-dependent activation of coagulation in mice. Sparkenbaugh EM, Chantrathammachart P, Wang S, Jonas W, Kirchhofer D, Gailani D, Gruber A, Kasthuri R, Key NS, Mackman N, Pawlinski R (2015) Haematologica 100(3): 308-14
    › Primary publication · 25596265 (PubMed) · PMC4349268 (PubMed Central)
  2. Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor. Puy C, Tucker EI, Matafonov A, Cheng Q, Zientek KD, Gailani D, Gruber A, McCarty OJ (2015) Blood 125(9): 1488-96
    › Primary publication · 25587039 (PubMed) · PMC4342360 (PubMed Central)
  3. Factor XI antisense oligonucleotide for prevention of venous thrombosis. Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI, FXI-ASO TKA Investigators (2015) N Engl J Med 372(3): 232-40
    › Primary publication · 25482425 (PubMed) · PMC4367537 (PubMed Central)
  4. Development of anti-factor XIII antibodies in a patient with hereditary factor XIII deficiency receiving therapy for chronic hepatitis C. Sosa R, Gailani D, Neff AT (2014) Haemophilia 20(6): e429-32
    › Primary publication · 25333572 (PubMed)
  5. Murine models in the evaluation of heparan sulfate-based anticoagulants. Gailani D, Cheng Q, Ivanov IS (2015) Methods Mol Biol : 483-96
    › Primary publication · 25325974 (PubMed) · PMC4365426 (PubMed Central)
  6. Prolylcarboxypeptidase independently activates plasma prekallikrein (fletcher factor). Wang J, Matafonov A, Madkhali H, Mahdi F, Watson D, Schmaier AH, Gailani D, Shariat-Madar Z (2014) Curr Mol Med 14(9): 1173-85
    › Primary publication · 25324000 (PubMed) · PMC4369925 (PubMed Central)
  7. Haemophilia A carriers demonstrate pathological and radiological evidence of structural joint changes. Gilbert L, Rollins L, Hilmes M, Luo Y, Gailani D, Debaun MR, Sidonio RF (2014) Haemophilia 20(6): e426-9
    › Primary publication · 25251752 (PubMed) · PMC4214880 (PubMed Central)
  8. Immediate recovery of acquired von Willebrand syndrome after left ventricular assist device explantation: implications for heart transplantation. Davis ME, Haglund NA, Tricarico NM, Matafonov A, Gailani D, Maltais S (2015) ASAIO J 61(1): e1-4
    › Primary publication · 25251586 (PubMed)
  9. Factor XI as a target for antithrombotic therapy. Bane CE, Gailani D (2014) Drug Discov Today 19(9): 1454-8
    › Primary publication · 24886766 (PubMed) · PMC4167190 (PubMed Central)
  10. The mechanism underlying activation of factor IX by factor XIa. Gailani D, Geng Y, Verhamme I, Sun MF, Bajaj SP, Messer A, Emsley J (2014) Thromb Res : S48-51
    › Primary publication · 24759143 (PubMed) · PMC4017667 (PubMed Central)
  11. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Matafonov A, Leung PY, Gailani AE, Grach SL, Puy C, Cheng Q, Sun MF, McCarty OJ, Tucker EI, Kataoka H, Renné T, Morrissey JH, Gruber A, Gailani D (2014) Blood 123(11): 1739-46
    › Primary publication · 24408325 (PubMed) · PMC3954054 (PubMed Central)
  12. Evidence for factor IX-independent roles for factor XIa in blood coagulation. Matafonov A, Cheng Q, Geng Y, Verhamme IM, Umunakwe O, Tucker EI, Sun MF, Serebrov V, Gruber A, Gailani D (2013) J Thromb Haemost 11(12): 2118-27
    › Primary publication · 24152424 (PubMed) · PMC3947433 (PubMed Central)
  13. Factor XI anion-binding sites are required for productive interactions with polyphosphate. Geng Y, Verhamme IM, Smith SA, Cheng Q, Sun M, Sheehan JP, Morrissey JH, Gailani D (2013) J Thromb Haemost 11(11): 2020-8
    › Primary publication · 24118982 (PubMed) · PMC3865764 (PubMed Central)
  14. Acquired factor V deficiency in a patient without evidence of a classical inhibitor. Sosa IR, Ellery P, Mast A, Neff AT, Gailani D (2014) Haemophilia 20(1): e81-3
    › Primary publication · 24118596 (PubMed) · PMC3870044 (PubMed Central)
  15. Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates. Puy C, Tucker EI, Wong ZC, Gailani D, Smith SA, Choi SH, Morrissey JH, Gruber A, McCarty OJ (2013) J Thromb Haemost 11(7): 1341-52
    › Primary publication · 23659638 (PubMed) · PMC3714337 (PubMed Central)
  16. Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice. Leung PY, Hurst S, Berny-Lang MA, Verbout NG, Gailani D, Tucker EI, Wang RK, McCarty OJ, Gruber A (2012) Transl Stroke Res 3(3): 381-9
    › Primary publication · 23634198 (PubMed) · PMC3637928 (PubMed Central)
  17. Analysis of the factor XI variant Arg184Gly suggests a structural basis for factor IX binding to factor XIa. Geng Y, Verhamme IM, Sun MF, Bajaj SP, Emsley J, Gailani D (2013) J Thromb Haemost 11(7): 1374-84
    › Primary publication · 23617568 (PubMed) · PMC4158700 (PubMed Central)
  18. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Crosby JR, Marzec U, Revenko AS, Zhao C, Gao D, Matafonov A, Gailani D, MacLeod AR, Tucker EI, Gruber A, Hanson SR, Monia BP (2013) Arterioscler Thromb Vasc Biol 33(7): 1670-8
    › Primary publication · 23559626 (PubMed) · PMC3717325 (PubMed Central)
  19. The dimeric structure of factor XI and zymogen activation. Geng Y, Verhamme IM, Smith SB, Sun MF, Matafonov A, Cheng Q, Smith SA, Morrissey JH, Gailani D (2013) Blood 121(19): 3962-9
    › Primary publication · 23515926 (PubMed) · PMC3650707 (PubMed Central)
  20. Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis. Luo D, Lin JS, Parent MA, Mullarky-Kanevsky I, Szaba FM, Kummer LW, Duso DK, Tighe M, Hill J, Gruber A, Mackman N, Gailani D, Smiley ST (2013) J Immunol 190(8): 4149-61
    › Primary publication · 23487423 (PubMed) · PMC3622124 (PubMed Central)
  21. Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site. Karuturi R, Al-Horani RA, Mehta SC, Gailani D, Desai UR (2013) J Med Chem 56(6): 2415-28
    › Primary publication · 23451707 (PubMed) · PMC3625964 (PubMed Central)
  22. Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa. Al-Horani RA, Ponnusamy P, Mehta AY, Gailani D, Desai UR (2013) J Med Chem 56(3): 867-78
    › Primary publication · 23316863 (PubMed) · PMC3574227 (PubMed Central)
  23. Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets. Duvernay M, Young S, Gailani D, Schoenecker J, Hamm HE, Hamm H (2013) Mol Pharmacol 83(4): 781-92
    › Primary publication · 23307185 (PubMed) · PMC3608438 (PubMed Central)
  24. A sequential mechanism for exosite-mediated factor IX activation by factor XIa. Geng Y, Verhamme IM, Messer A, Sun MF, Smith SB, Bajaj SP, Gailani D (2012) J Biol Chem 287(45): 38200-9
    › Primary publication · 22961984 (PubMed) · PMC3488089 (PubMed Central)
  25. Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis. Rabey FM, Gadepalli RS, Diano S, Cheng Q, Tabrizian T, Gailani D, Rimoldi JM, Shariat-Madar Z (2012) Curr Med Chem 19(24): 4194-206
    › Primary publication · 22664251 (PubMed) · PMC4367813 (PubMed Central)
  26. Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Tucker EI, Verbout NG, Leung PY, Hurst S, McCarty OJ, Gailani D, Gruber A (2012) Blood 119(20): 4762-8
    › Primary publication · 22442348 (PubMed) · PMC3367876 (PubMed Central)
  27. A cofactor for factor XI activation. Gailani D (2011) Blood 118(26): 6730-1
    › Primary publication · 22194395 (PubMed)
  28. Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis. Luo D, Szaba FM, Kummer LW, Johnson LL, Tucker EI, Gruber A, Gailani D, Smiley ST (2012) Infect Immun 80(1): 91-9
    › Primary publication · 22006565 (PubMed) · PMC3255681 (PubMed Central)
  29. Acquired factor XI deficiency in a child with membranoproliferative glomerulonephritis. McManus MP, Frantz C, Gailani D (2012) Pediatr Blood Cancer 59(1): 173-5
    › Primary publication · 21850674 (PubMed) · PMC4364028 (PubMed Central)
  30. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Revenko AS, Gao D, Crosby JR, Bhattacharjee G, Zhao C, May C, Gailani D, Monia BP, MacLeod AR (2011) Blood 118(19): 5302-11
    › Primary publication · 21821705 (PubMed) · PMC4425441 (PubMed Central)
  31. Activated factor XI inhibits chemotaxis of polymorphonuclear leukocytes. Itakura A, Verbout NG, Phillips KG, Insall RH, Gailani D, Tucker EI, Gruber A, McCarty OJ (2011) J Leukoc Biol 90(5): 923-7
    › Primary publication · 21807745 (PubMed) · PMC3206472 (PubMed Central)
  32. Factor XI and XII as antithrombotic targets. Müller F, Gailani D, Renné T (2011) Curr Opin Hematol 18(5): 349-55
    › Primary publication · 21730835 (PubMed) · PMC4364027 (PubMed Central)
  33. Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica. Luo D, Szaba FM, Kummer LW, Plow EF, Mackman N, Gailani D, Smiley ST (2011) J Immunol 187(4): 1866-76
    › Primary publication · 21724997 (PubMed) · PMC3150340 (PubMed Central)
  34. Activation of factor XI by products of prothrombin activation. Matafonov A, Sarilla S, Sun MF, Sheehan JP, Serebrov V, Verhamme IM, Gailani D (2011) Blood 118(2): 437-45
    › Primary publication · 21527525 (PubMed) · PMC3138693 (PubMed Central)
  35. Laminin promotes coagulation and thrombus formation in a factor XII-dependent manner. White-Adams TC, Berny MA, Patel IA, Tucker EI, Gailani D, Gruber A, McCarty OJ (2010) J Thromb Haemost 8(6): 1295-301
    › Primary publication · 20796202 (PubMed) · PMC4367539 (PubMed Central)
  36. Evidence against a protein in plasma that is a product of a factor XI mRNA splice variant missing exons 6 and 7. Gailani D, Sun MF, Cheng Q, Matafonov A, Tucker EI, Gruber A, Emsley J (2010) Blood 116(7): 1185-6; author reply 1186-7
    › Primary publication · 20724549 (PubMed) · PMC2938133 (PubMed Central)
  37. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF, White-Adams TC, Smith SA, Hanson SR, McCarty OJ, Renné T, Gruber A, Gailani D (2010) Blood 116(19): 3981-9
    › Primary publication · 20634381 (PubMed) · PMC2981546 (PubMed Central)
  38. Structure and function of factor XI. Emsley J, McEwan PA, Gailani D (2010) Blood 115(13): 2569-77
    › Primary publication · 20110423 (PubMed) · PMC4828079 (PubMed Central)
  39. Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II. Sarilla S, Habib SY, Kravtsov DV, Matafonov A, Gailani D, Verhamme IM (2010) J Biol Chem 285(11): 8278-89
    › Primary publication · 20053992 (PubMed) · PMC2832979 (PubMed Central)
  40. Update on the physiology and pathology of factor IX activation by factor XIa. Smith SB, Gailani D (2008) Expert Rev Hematol 1(1): 87-98
    › Primary publication · 19714257 (PubMed) · PMC2731971 (PubMed Central)
  41. Factor IX binding to collagen. Gailani D (2009) J Thromb Haemost 7(11): 1840-2
    › Primary publication · 19694943 (PubMed) · PMC2857663 (PubMed Central)
  42. Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). White-Adams TC, Berny MA, Tucker EI, Gertz JM, Gailani D, Urbanus RT, de Groot PG, Gruber A, McCarty OJ (2009) Arterioscler Thromb Vasc Biol 29(10): 1602-7
    › Primary publication · 19661487 (PubMed) · PMC2756776 (PubMed Central)
  43. Structural and functional features of factor XI. Gailani D, Smith SB (2009) J Thromb Haemost : 75-8
    › Primary publication · 19630773 (PubMed) · PMC2849299 (PubMed Central)
  44. Factor XI contributes to thrombin generation in the absence of factor XII. Kravtsov DV, Matafonov A, Tucker EI, Sun MF, Walsh PN, Gruber A, Gailani D (2009) Blood 114(2): 452-8
    › Primary publication · 19351955 (PubMed) · PMC2714215 (PubMed Central)
  45. Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor. Yang L, Sun MF, Gailani D, Rezaie AR (2009) Biochemistry 48(7): 1517-24
    › Primary publication · 19178150 (PubMed) · PMC2654577 (PubMed Central)
  46. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Tucker EI, Marzec UM, White TC, Hurst S, Rugonyi S, McCarty OJ, Gailani D, Gruber A, Hanson SR (2009) Blood 113(4): 936-44
    › Primary publication · 18945968 (PubMed) · PMC2630279 (PubMed Central)
  47. Evolution of the contact phase of vertebrate blood coagulation. Ponczek MB, Gailani D, Doolittle RF (2008) J Thromb Haemost 6(11): 1876-83
    › Primary publication · 18761718 (PubMed) · PMC2666913 (PubMed Central)
  48. Factor XI protein in human pancreas and kidney. Cheng Q, Kantz J, Poffenberger G, Powers AC, Gailani D (2008) Thromb Haemost 100(1): 158-60
    › Primary publication · 18612554 (PubMed) · PMC2690650 (PubMed Central)
  49. Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. Tucker EI, Gailani D, Hurst S, Cheng Q, Hanson SR, Gruber A (2008) J Infect Dis 198(2): 271-4
    › Primary publication · 18491973 (PubMed) · PMC2654284 (PubMed Central)
  50. Characterization of Novel Forms of Coagulation Factor XIa: independence of factor XIa subunits in factor IX activation. Smith SB, Verhamme IM, Sun MF, Bock PE, Gailani D (2008) J Biol Chem 283(11): 6696-705
    › Primary publication · 18192270 (PubMed) · PMC2633474 (PubMed Central)
  51. Functional role of residue 193 (chymotrypsin numbering) in serine proteases: influence of side chain length and beta-branching on the catalytic activity of blood coagulation factor XIa. Schmidt AE, Sun MF, Ogawa T, Bajaj SP, Gailani D (2008) Biochemistry 47(5): 1326-35
    › Primary publication · 18186617 (PubMed) · PMC2885443 (PubMed Central)
  52. Defective binding of factor XI-N248 to activated human platelets. Sun MF, Ho D, Martincic D, Ware RE, Walsh PN, Gailani D (2007) Blood 110(13): 4164
    › Primary publication · 18056845 (PubMed)
  53. Intrinsic pathway of coagulation and arterial thrombosis. Gailani D, Renné T (2007) Arterioscler Thromb Vasc Biol 27(12): 2507-13
    › Primary publication · 17916770 (PubMed)
  54. Factor XI/ADAMTS13 complexes are quantitatively insignificant in human plasma. Anderson PJ, Gailani D, Feys HB, Gao W, Majerus EM, Vanhoorelbeke K, Sadler JE (2007) Haematologica 92(10): 1419-22
    › Primary publication · 17768109 (PubMed)
  55. Role of Factor XII in hemostasis and thrombosis: clinical implications. Renné T, Gailani D (2007) Expert Rev Cardiovasc Ther 5(4): 733-41
    › Primary publication · 17605651 (PubMed)
  56. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? Gailani D, Renné T (2007) J Thromb Haemost 5(6): 1106-12
    › Primary publication · 17388803 (PubMed)
  57. A cross-reactive material positive variant of coagulation factor XI (FXIP520L) with a catalytic defect. Gailani D, Schmidt A, Sun MF, Bolton-Maggs PH, Bajaj SP (2007) J Thromb Haemost 5(4): 781-7
    › Primary publication · 17229051 (PubMed)
  58. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. Wang X, Smith PL, Hsu MY, Gailani D, Schumacher WA, Ogletree ML, Seiffert DA (2006) J Thromb Haemost 4(9): 1982-8
    › Primary publication · 16961605 (PubMed)
  59. Contributions of basic amino acids in the autolysis loop of factor XIa to serpin specificity. Rezaie AR, Sun MF, Gailani D (2006) Biochemistry 45(31): 9427-33
    › Primary publication · 16878977 (PubMed)
  60. Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass. Donahue BS, Gailani D, Mast AE (2006) J Thromb Haemost 4(5): 1011-6
    › Primary publication · 16689752 (PubMed)
  61. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, Renné C, Gailani D, Nieswandt B, Renné T (2006) J Exp Med 203(3): 513-8
    › Primary publication · 16533887 (PubMed) · PMC2118228 (PubMed Central)
  62. The intrinsic pathway of coagulation is essential for thrombus stability in mice. Renné T, Nieswandt B, Gailani D (2006) Blood Cells Mol Dis 36(2): 148-51
    › Primary publication · 16466946 (PubMed)
  63. Defective thrombus formation in mice lacking coagulation factor XII. Renné T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B (2005) J Exp Med 202(2): 271-81
    › Primary publication · 16009717 (PubMed) · PMC2213000 (PubMed Central)
  64. The effects of intrinsic pathway protease deficiencies on plasminogen-deficient mice. Cheng Q, Zhao Y, Lawson WE, Polosukhin VV, Johnson JE, Blackwell TS, Gailani D (2005) Blood 106(9): 3055-7
    › Primary publication · 15985536 (PubMed) · PMC1895339 (PubMed Central)
  65. Exosite-mediated substrate recognition of factor IX by factor XIa. The factor XIa heavy chain is required for initial recognition of factor IX. Ogawa T, Verhamme IM, Sun MF, Bock PE, Gailani D (2005) J Biol Chem 280(25): 23523-30
    › Primary publication · 15829482 (PubMed) · PMC2292466 (PubMed Central)
  66. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu MY, Smith PL, Seiffert DA, Schumacher WA, Ogletree ML, Gailani D (2005) J Thromb Haemost 3(4): 695-702
    › Primary publication · 15733058 (PubMed)
  67. A classification system for cross-reactive material-negative factor XI deficiency. Kravtsov DV, Monahan PE, Gailani D (2005) Blood 105(12): 4671-3
    › Primary publication · 15728123 (PubMed) · PMC1895004 (PubMed Central)
  68. Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI-Glu555): a cross-reactive material positive variant defective in factor IX activation. Zivelin A, Ogawa T, Bulvik S, Landau M, Toomey JR, Lane J, Seligsohn U, Gailani D (2004) J Thromb Haemost 2(10): 1782-9
    › Primary publication · 15456490 (PubMed)
  69. Do platelets synthesize factor XI? Gailani D, Zivelin A, Sinha D, Walsh PN (2004) J Thromb Haemost 2(10): 1709-12
    › Primary publication · 15456479 (PubMed)
  70. Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI. Baglia FA, Gailani D, López JA, Walsh PN (2004) J Biol Chem 279(44): 45470-6
    › Primary publication · 15317813 (PubMed)
  71. Structural role of Gly(193) in serine proteases: investigations of a G555E (GLY193 in chymotrypsin) mutant of blood coagulation factor XI. Schmidt AE, Ogawa T, Gailani D, Bajaj SP (2004) J Biol Chem 279(28): 29485-92
    › Primary publication · 15090552 (PubMed)
  72. Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Kravtsov DV, Wu W, Meijers JC, Sun MF, Blinder MA, Dang TP, Wang H, Gailani D (2004) Blood 104(1): 128-34
    › Primary publication · 15026311 (PubMed)
  73. Tissue factor and platelet glycoprotein Ib-alpha alleles are associated with age at first coronary bypass operation. Donahue BS, Byrne DW, Gailani D, George AL (2003) Anesthesiology 99(6): 1287-94
    › Primary publication · 14639140 (PubMed)
  74. Factor XI apple domains and protein dimerization. Cheng Q, Sun MF, Kravtsov DV, Aktimur A, Gailani D (2003) J Thromb Haemost 1(11): 2340-7
    › Primary publication · 14629467 (PubMed)
  75. Common single nucleotide polymorphisms in the promoter region of the human factor XI gene. Tarumi T, Kravtsov DV, Moore JH, Williams SM, Gailani D (2003) J Thromb Haemost 1(8): 1854-6
    › Primary publication · 12911610 (PubMed)
  76. Factor V Leiden protects against blood loss and transfusion after cardiac surgery. Donahue BS, Gailani D, Higgins MS, Drinkwater DC, George AL (2003) Circulation 107(7): 1003-8
    › Primary publication · 12600914 (PubMed)
  77. The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa. Aktimur A, Gabriel MA, Gailani D, Toomey JR (2003) J Biol Chem 278(10): 7981-7
    › Primary publication · 12496253 (PubMed)
  78. Fine mapping of the H-kininogen binding site in plasma prekallikrein apple domain 2. Renné T, Sugiyama A, Gailani D, Jahnen-Dechent W, Walter U, Müller-Esterl W (2002) Int Immunopharmacol 2(13-14): 1867-73
    › Primary publication · 12489801 (PubMed)
  79. Molecular cloning and biochemical characterization of rabbit factor XI. Sinha D, Marcinkiewicz M, Gailani D, Walsh PN (2002) Biochem J 367(Pt 1): 49-56
    › Primary publication · 12084014 (PubMed) · PMC1222859 (PubMed Central)
  80. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Rosen ED, Gailani D, Castellino FJ (2002) Thromb Haemost 87(4): 774-6
    › Primary publication · 12008966 (PubMed)
  81. Cloning and characterization of the human factor XI gene promoter: transcription factor hepatocyte nuclear factor 4alpha (HNF-4alpha ) is required for hepatocyte-specific expression of factor XI. Tarumi T, Kravtsov DV, Zhao M, Williams SM, Gailani D (2002) J Biol Chem 277(21): 18510-6
    › Primary publication · 11891231 (PubMed)
  82. Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein. Renné T, Gailani D, Meijers JC, Müller-Esterl W (2002) J Biol Chem 277(7): 4892-9
    › Primary publication · 11733491 (PubMed)
  83. Defective binding of factor XI-N248 to activated human platelets. Sun MF, Baglia FA, Ho D, Martincic D, Ware RE, Walsh PN, Gailani D (2001) Blood 98(1): 125-9
    › Primary publication · 11418471 (PubMed)
  84. Model for a factor IX activation complex on blood platelets: dimeric conformation of factor XIa is essential. Gailani D, Ho D, Sun MF, Cheng Q, Walsh PN (2001) Blood 97(10): 3117-22
    › Primary publication · 11342438 (PubMed)
  85. Activation of factor IX by factor XIa. Gailani D (2000) Trends Cardiovasc Med 10(5): 198-204
    › Primary publication · 11282295 (PubMed)
  86. Gene targeting in hemostasis. factor XI. Gailani D (2001) Front Biosci : D201-7
    › Primary publication · 11171549 (PubMed)
  87. The characterization of mice with a targeted combined deficiency of protein c and factor XI. Chan JC, Ganopolsky JG, Cornelissen I, Suckow MA, Sandoval-Cooper MJ, Brown EC, Noria F, Gailani D, Rosen ED, Ploplis VA, Castellino FJ (2001) Am J Pathol 158(2): 469-79
    › Primary publication · 11159184 (PubMed) · PMC1850297 (PubMed Central)
  88. Conserved worldwide linkage disequilibrium in the human factor XI gene. Tarumi T, Martincic D, Whitlock JA, Addy JH, Williams SM, Gailani D (2000) Genomics 70(2): 269-72
    › Primary publication · 11112356 (PubMed)
  89. Familial thrombophilia associated with fibrinogen paris V: Dusart syndrome. Tarumi T, Martincic D, Thomas A, Janco R, Hudson M, Baxter P, Gailani D (2000) Blood 96(3): 1191-3
    › Primary publication · 10910944 (PubMed)
  90. The role of high molecular weight kininogen and prothrombin as cofactors in the binding of factor XI A3 domain to the platelet surface. Ho DH, Badellino K, Baglia FA, Sun MF, Zhao MM, Gailani D, Walsh PN (2000) J Biol Chem 275(33): 25139-45
    › Primary publication · 10823824 (PubMed)
  91. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P (2000) Blood 95(2): 564-8
    › Primary publication · 10627463 (PubMed)
  92. Identification of amino acids in the factor XI apple 3 domain required for activation of factor IX. Sun MF, Zhao M, Gailani D (1999) J Biol Chem 274(51): 36373-8
    › Primary publication · 10593931 (PubMed)
  93. Factor XI messenger RNA in human platelets. Martincic D, Kravtsov V, Gailani D (1999) Blood 94(10): 3397-404
    › Primary publication · 10552949 (PubMed)
  94. Anticoagulant-induced skin necrosis in a patient with hereditary deficiency of protein S. Gailani D, Reese EP (1999) Am J Hematol 60(3): 231-6
    › Primary publication · 10072117 (PubMed)
  95. Characterization of a heparin binding site on the heavy chain of factor XI. Zhao M, Abdel-Razek T, Sun MF, Gailani D (1998) J Biol Chem 273(47): 31153-9
    › Primary publication · 9813019 (PubMed)
  96. Identification of mutations and polymorphisms in the factor XI genes of an African American family by dideoxyfingerprinting. Martincic D, Zimmerman SA, Ware RE, Sun MF, Whitlock JA, Gailani D (1998) Blood 92(9): 3309-17
    › Primary publication · 9787168 (PubMed)
  97. A murine model of factor XI deficiency. Gailani D, Lasky NM, Broze GJ (1997) Blood Coagul Fibrinolysis 8(2): 134-44
    › Primary publication · 9518045 (PubMed)
  98. Advances and dilemmas in factor XI. Gailani D (1994) Curr Opin Hematol 1(5): 347-53
    › Primary publication · 9371304 (PubMed)
  99. A comparison of murine and human factor XI. Gailani D, Sun MF, Sun Y (1997) Blood 90(3): 1055-64
    › Primary publication · 9242536 (PubMed)
  100. Identification of a factor IX binding site on the third apple domain of activated factor XI. Sun Y, Gailani D (1996) J Biol Chem 271(46): 29023-8
    › Primary publication · 8910554 (PubMed)
  101. Effects of glycosaminoglycans on factor XI activation by thrombin. Gailani D, Broze GJ (1993) Blood Coagul Fibrinolysis 4(1): 15-20
    › Primary publication · 8457645 (PubMed)
  102. Factor XII-independent activation of factor XI in plasma: effects of sulfatides on tissue factor-induced coagulation. Gailani D, Broze GJ (1993) Blood 82(3): 813-9
    › Primary publication · 8338946 (PubMed)
  103. The role of factor XI in coagulation. Broze GJ, Gailani D (1993) Thromb Haemost 70(1): 72-4
    › Primary publication · 8236118 (PubMed)
  104. Factor XI activation by thrombin and factor XIa. Gailani D, Broze GJ (1993) Semin Thromb Hemost 19(4): 396-404
    › Primary publication · 8140432 (PubMed)
  105. Complementary DNA sequencing of canine tissue factor pathway inhibitor reveals a unique nanomeric repetitive sequence between the second and third Kunitz domains. Girard TJ, Gailani D, Broze GJ (1994) Biochem J : 923-8
    › Primary publication · 7980463 (PubMed) · PMC1137634 (PubMed Central)
  106. A phorbol ester tolerant (PET) variant of HL-60 promyelocytes. Macfarlane DE, Gailani D, Vann K (1988) Br J Haematol 68(3): 291-302
    › Primary publication · 3162684 (PubMed)
  107. Absence of phorbol ester-induced down-regulation of myc protein in the phorbol ester-tolerant mutant of HL-60 promyelocytes. Gailani D, Cadwell FJ, O'Donnell PS, Hromas RA, Macfarlane DE (1989) Cancer Res 49(19): 5329-33
    › Primary publication · 2670202 (PubMed)
  108. Identification of phosphoprotein NP33 as a nucleus-associated ribosomal S6 protein and its phosphorylation in hematopoietic cells. Macfarlane DE, Gailani D (1990) Cancer Res 50(10): 2895-900
    › Primary publication · 2334893 (PubMed)
  109. P47 phosphoprotein of blood platelets (pleckstrin) is a major target for phorbol ester-induced protein phosphorylation in intact platelets, granulocytes, lymphocytes, monocytes and cultured leukaemic cells: absence of P47 in non-haematopoietic cells. Gailani D, Fisher TC, Mills DC, Macfarlane DE (1990) Br J Haematol 74(2): 192-202
    › Primary publication · 2317454 (PubMed)
  110. An IgG inhibitor against coagulation factor XIII: resolution of bleeding after plasma immunoadsorption with staphylococcal protein A. Gailani D (1992) Am J Med 92(1): 110-2
    › Primary publication · 1731502 (PubMed)
  111. Factor XI activation in a revised model of blood coagulation. Gailani D, Broze GJ (1991) Science 253(5022): 909-12
    › Primary publication · 1652157 (PubMed)